What’s Next for Osmotica Pharmaceuticals plc (OSMT) After Touching All-Time Low?

The stock of Osmotica Pharmaceuticals plc (NASDAQ:OSMT) reached all time low today, May, 8 and still has $3.36 target or 5.00 % below today’s $3.53 share price. This indicates more downside for the $185.58 million company. This technical setup was reported by Barchart.com. If the $3.36 PT is reached, the company will be worth $9.28M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only.

The stock decreased 7.98% or $0.3064 during the last trading session, reaching $3.5336. About 477,480 shares traded or 312.07% up from the average. Osmotica Pharmaceuticals plc (NASDAQ:OSMT) has 0.00% since May 8, 2018 and is . It has underperformed by 4.37% the S&P500.

Analysts await Osmotica Pharmaceuticals plc (NASDAQ:OSMT) to report earnings on May, 9 after the close.

More notable recent Osmotica Pharmaceuticals plc (NASDAQ:OSMT) news were published by: Seekingalpha.com which released: “Wall Street Breakfast: What Moved Markets This Week – Seeking Alpha” on March 30, 2019, also Seekingalpha.com with their article: “Osmotica down 37% after Q4 report, mixed results for arbaclofen – Seeking Alpha” published on March 28, 2019, Benzinga.com published: “Jefferies Sees Opportunity In Marinus Pharmaceuticals (NASDAQ:MRNS): 4 Reasons Why – Benzinga” on March 05, 2019. More interesting news about Osmotica Pharmaceuticals plc (NASDAQ:OSMT) were released by: Nasdaq.com and their article: “Extended release drug maker Osmotica Pharmaceuticals prices half-sized IPO at $7 – Nasdaq” published on October 18, 2018 as well as Benzinga.com‘s news article titled: “Tilray Announces Support Of 2 Clinical Studies In Australia, Canada (NASDAQ:TLRY) – Benzinga” with publication date: April 01, 2019.

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, makes, and commercializes specialty products that target markets with underserved patient populations. The company has market cap of $185.58 million. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. It currently has negative earnings. The Company’s non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for nutritional requirements during pregnancy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.